Ad Header



The Pulse of the Pharmaceutical Industry

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

Written by: | | Dated: Wednesday, May 30th, 2018


(Reuters) – AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.

Fasenra failed to meet its target in the final-stage trial, named Galathea, this month.


Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom